Pharma: Other news to note
Monday, February 24, 2014
Teva Pharmaceutical Industries Ltd., of Jerusalem, said the European Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Duoresp Spiromax (budesonide and formoterol fumarate dehydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease when a combination inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.